These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11181881)

  • 1. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate.
    Windhagen A; Maniak S; Marckmann S; Lindert RB; Heidenreich F; Blasczyk R
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):415-6. PubMed ID: 11181881
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychiatric manifestations in multiple sclerosis patients and multiple sclerosis in psychiatric patient.
    Fragoso YD; Brooks JB
    Arq Neuropsiquiatr; 2009 Dec; 67(4):1167-8. PubMed ID: 20069241
    [No Abstract]   [Full Text] [Related]  

  • 6. Glatiramer acetate: a novel therapeutic approach in Crohn's disease?
    Neesse A; Michl P; Kunsch S; Gress TM; Steinkamp M
    Inflamm Bowel Dis; 2009 Jan; 15(1):156-7. PubMed ID: 18626969
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms of action of glatiramer acetate in multiple sclerosis.
    Neuhaus O; Farina C; Wekerle H; Hohlfeld R
    Neurology; 2001 Mar; 56(6):702-8. PubMed ID: 11288751
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate.
    Krečak I; Celić-Bunikić S; Skelin M; Lucijanić M; Verstovsek S; Kušec R
    Ann Hematol; 2022 Aug; 101(8):1885-1886. PubMed ID: 35461396
    [No Abstract]   [Full Text] [Related]  

  • 9. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months.
    Fiore AP; Fragoso YD
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):738-40. PubMed ID: 16258646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
    Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
    Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
    Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.
    Ziemssen T
    Adv Exp Med Biol; 2004; 541():111-34. PubMed ID: 14977211
    [No Abstract]   [Full Text] [Related]  

  • 16. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM; Rovaris M; Filippi M
    Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 18. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Charles JA; Tremlett H; Lu E; Guimond C; Sadovnick AD
    Neurology; 2013 Mar; 80(11):1068-9. PubMed ID: 23479468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):61-2. PubMed ID: 9217693
    [No Abstract]   [Full Text] [Related]  

  • 20. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.